Transgenic mouse models have emerged as plausible alternatives to long-term bioassays for carcinogenicity. Three transgenic lines evaluated to date have shown a clear capability to discriminate between carcinogens and noncarcinogens, using long-term bioassay results as the standard. The data also suggest that the transgenic lines will not fully duplicate long-term bioassay results. It is proposed that these models do not respond to chemicals that have induced highly restricted species or strain-specific tumor responses in mice or rats. Rather, the value of the transgenic models is predicated on a preferential response to transspecies carcinogens (i.e., those positive in both rats and mice, often including tumors in the same tissues). Thus, although results in transgenic models may not be completely concordant with long-term bioassays, the data can be used effectively in chemical and drug safety assessments. Further, it is proposed that validation of the models is readily achievable via ongoing studies. 
Introduction
In the hierarchy of data used in the identification of causes of human cancer, clinical observation and epidemiologic studies provide the most definitive sources. However, because these methods are intrinsically retrospective, the long-term two-species rodent bioassay is the most generally accepted standard for identifying potential carcinogens or, conversely, recognizing chemicals, drugs, or environmental factors that probably do not represent a potential human carcinogen. In this context, the application of in vivo alternative methods refers specifically to alternatives to the conventional rodent bioassay.
We have learned a great deal about issues of validation and evaluation of alternatives through the search for in vitro methods that can replace or complement long-term rodent studies, principally in the field of genetic toxicology. It is estimated that over the past two decades at least 100 different assays have been developed and proposed to serve as alternative systems. The evaluation of these methods has been at times controversial, or at best difficult, but the efforts nonetheless serve as a guide to the types of issues that must be resolved for methods to be generally used in place of 2-year rodent bioassays. Substantial amounts of literature were created on genetic toxicity test methods and various aspects have been reviewed elsewhere (1, 2) . One (3, 4) . Subsequently, additional information has been provided for in vivo assays such as induction of chromosome aberrations or micronuclei (5) . The objectivity of the effort included the use of coded samples and, when possible, samples from the same lot of chemical as were used in the 2-year bioassay. Chemicals were chosen for which definitive 2-year bioassay results existed and samples were tested under code. The results of this extended evaluation served to verify the hypothesis that a significant portion of rodent carcinogens probably act via nonmutagenic mechanisms and that existing in vitro assays were inadequate to detect such nongenotoxic carcinogens. However, the results summarized elsewhere also permitted an intertest comparison of the four genotoxicity assays that were used (3, 4) . An interesting aspect of the consequences of this effort relates to the mouse lymphoma (TK+'-) in vitro mutation assay, which demonstrated a relatively high level of false positive results. That is, the mouse lymphoma assay responded to a high proportion of rodent noncarcinogens that were not detected by the other systems. Despite these results, the mouse lymphoma assay continues to be utilized for drug and chemical safety evaluation (6) . One reason for this paradox appears to be the general belief that the mouse lymphoma assay detects not only point mutational effects of chemicals but also responds to agents that have some clastogenic potential (7 The zetaglobin promoted v-Ha-ras transgenic mouse line (Tg.AC) possesses a unique phenotype that is the product of two primary properties that include the activation of the mutated ras gene via a fetal globin promoter and the site of integration (13) . The induction of skin papillomas by topical exposure to tumor promoters and carcinogens appears directly related to functional properties of the zetaglobin promoter and the location of the site of integration in a domain that permits the transgene to be expressed in the epidermis. The model is consistent with the role of the mutated endogenous Ha-ras gene in skin tumor induction in the conventional two-stage initiation-promotion process in mice (18) . That is, mutation of the endogenous (11, 13, 14, 16) . It is also possible to obtain the latest information available on the studies in transgenic models conducted by the NIEHS/U.S. NTP via the Internet (22). This Internet site will be used to solicit nominations for further studies in transgenics, list chemicals currently being studied, and provide summary results as they become available.
Validation of Transgenic Bioassays
The basic proposition of this paper is that although the data are limited for the number of chemicals that have been evaluated in the three transgenic models, the results are sufficient to allow incorporation of results from these models into the safety assessment of chemicals and drugs. The safety assessment, hazard identification, and risk evaluation processes are intrinsically subjective and by their very nature must be done by weight of evidence. That is, all the available data on the properties and biologic effects of the chemical or drug must be used in evaluating human risk (1, 2) . There is no proscriptive formula to effectively safeguard human health and permit the valid utilization of chemicals and drugs. Although the rodent bioassay is viewed by some as the gold standard for safety assessment, it is actually one tool with which to judge the biologic effects of chemicals. It is obvious that rodents are imperfect surrogates for the human population. Results in the rodent can be validly compared to those in humans for a variety of substances, and though many genetic determinants are highly conserved between the species, there are many more genetic differences that significantly impact on judgments of hazard evaluation. As stated above, the principal manifestations of these differences in regard to the bioassay are the high background rates of spontaneous tumors and evidence of strain-specific responses to chemicals. These observations do not invalidate the bioassay, as known human carcinogens are also carcinogenic in rodent models, but conversely, it does not mean that every effect observed in the rodent is necessarily predictive of human health hazard. We have advocated that the transgenic models can complement and eventually supplant the use of the long-term rodent bioassays by minimizing strain-specific responses without significantly diminishing the capability to recognize the transspecies carcinogens that are likely the most proximate human health hazard identified in the long-term bioassay. Those who hold to a literal interpretation of bioassay results, i.e., any effect in the rodent is probably indicative of a human health risk, will not endorse the use of such models because they are predicated on the principle that they will not respond to the majority of chemicals that have shown highly strain-or site-specific effects in the 2-year bioassay. understanding, these two alternatives cannot be discriminated effectively, but as additional experience with a greater variety of chemicals or drugs is obtained, distinction between these possibilities should be resolvable.
The Tg.AC transgenic model has shown clear-cut responses to both mutagenic and nonmutagenic chemicals administered topically. Apparently, induction of papillomas is a direct consequence of the activation of transgene expression in a specific population of cells that appear to reside predominately within the upper follicular epithelium.
In summary, the available though limited data for chemical effects in transgenic mouse models indicate that selected models can play a role in drug and chemical safety evaluation. The validation of the models is an evolving process, but sufficient understanding of the mechanisms of tumor induction in transgenic lines exists to make plausible predictions for the outcome of transgenic bioassays.
